全文获取类型
收费全文 | 33286篇 |
免费 | 2097篇 |
国内免费 | 865篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 443篇 |
妇产科学 | 315篇 |
基础医学 | 1995篇 |
口腔科学 | 212篇 |
临床医学 | 2787篇 |
内科学 | 7551篇 |
皮肤病学 | 327篇 |
神经病学 | 2306篇 |
特种医学 | 492篇 |
外国民族医学 | 1篇 |
外科学 | 2186篇 |
综合类 | 3345篇 |
一般理论 | 3篇 |
预防医学 | 2337篇 |
眼科学 | 170篇 |
药学 | 9528篇 |
20篇 | |
中国医学 | 1422篇 |
肿瘤学 | 756篇 |
出版年
2023年 | 575篇 |
2022年 | 932篇 |
2021年 | 1466篇 |
2020年 | 1182篇 |
2019年 | 1502篇 |
2018年 | 1570篇 |
2017年 | 1350篇 |
2016年 | 1108篇 |
2015年 | 1147篇 |
2014年 | 2501篇 |
2013年 | 3149篇 |
2012年 | 1871篇 |
2011年 | 2072篇 |
2010年 | 1594篇 |
2009年 | 1426篇 |
2008年 | 1417篇 |
2007年 | 1306篇 |
2006年 | 1068篇 |
2005年 | 974篇 |
2004年 | 784篇 |
2003年 | 723篇 |
2002年 | 542篇 |
2001年 | 500篇 |
2000年 | 395篇 |
1999年 | 329篇 |
1998年 | 287篇 |
1997年 | 289篇 |
1996年 | 265篇 |
1995年 | 243篇 |
1994年 | 216篇 |
1993年 | 249篇 |
1992年 | 222篇 |
1991年 | 176篇 |
1990年 | 166篇 |
1989年 | 150篇 |
1988年 | 158篇 |
1987年 | 104篇 |
1986年 | 114篇 |
1985年 | 210篇 |
1984年 | 244篇 |
1983年 | 200篇 |
1982年 | 191篇 |
1981年 | 186篇 |
1980年 | 155篇 |
1979年 | 154篇 |
1978年 | 153篇 |
1977年 | 131篇 |
1976年 | 125篇 |
1975年 | 119篇 |
1974年 | 83篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
41.
A. Guerrero Gómez N. González Jaramillo J.A. Castro Pérez 《Revista espa?ola de anestesiología y reanimación》2019,66(1):10-17
Introduction
The fast track / ultra-fast-track protocols are techniques used to optimise the patient care process and a quick recovery after cardiac surgery. They are one of the mainstays of efficient practice. With their use, the length of hospital and intensive care unit (ICU) stays are reduced, with a direct impact on costs and the quality of the health service.Objective
To compare the length of stay in the ICU, length of hospital stay, and post-operative mortality in ultra-fast-track extubated (uFTE) patients and those with conventional extubation (CE) after cardiac surgery.Methods
Longitudinal, analytical, retrospective study was conducted, with the period between the time of surgery and discharge being included as the study period.Results
A total of 396 patients older than 18 years who required cardiac surgery were included, of whom 207 patients had (uFTE) and 189 had CE. Although the groups were not comparable due to the statistical differences found, when performing the multivariate adjustment, uFTE maintained its statistical independence and was associated with lower cardiovascular morbidity, such as myocardial ischaemia (95% CI: 0.37-0.86; P = .01) and lower post-surgical vasopressor requirement (95% CI: 0.18-0.49; P < .01). No significant differences were found in the length of hospital stay, ICU stay, or post-operative mortality in the ICU.Conclusion
Implementing the uFTE strategy, decreases cardiovascular morbidity and vasopressor requirement. The change to uFTE should be accompanied by changes in models and practices in patient recovery to standardised protocols. This study shows that uFTE did not reduce the length of ICU stay, hospital stay, or mortality. 相似文献42.
目的 了解解放军总医院抗震颤麻痹药物的应用情况与用药趋势。方法 采用世界卫生组织(WHO)推荐的以限定日剂量(DDD)为指标的分析方法,对2015-2017年解放军总医院抗震颤麻痹药物的销售金额、用药频度(DDDs)、日均费用(DDC)及排序比(B/A)等进行统计分析。结果 普拉克索、多巴丝肼和恩他卡朋的用药金额始终处于前3位,普拉克索的用药金额逐渐上升,卡比多巴/左旋多巴的用药金额逐渐下降;DDDs排序列前2位的是多巴丝肼和司来吉兰,多巴丝肼的DDDs逐年上升,一直处于第1位;2015-2016年各种抗震颤麻痹药物的DDC较为稳定,2016-2017年各种抗震颤麻痹药物的DDC开始略有下降;除普拉克索和恩他卡朋的B/A始终小于1.00,其他抗震颤麻痹药物的B/A均在1.00以上波动。结论 解放军总医院抗震颤麻痹药物的使用较为合理,其中多巴丝肼、普拉克索和司来吉兰具有很好的市场前景。 相似文献
43.
《Saudi Pharmaceutical Journal》2020,28(10):1243-1252
The novel coronavirus outbreak has reported to be rapidly spreading across the countries and becomes a foremost community health alarm. At present, no vaccine or specific drug is on hand for the treatment of this infectious disease. This review investigates the drugs, which are being evaluated and found to be effective against nCOVID-19 infection. A thorough literature search was performedon the recently published research papers in between January 2020 to May 2020, through various databases like “Science Direct”, “Google Scholar”, “PubMed”,“Medline”, “Web of Science”, and “World Health Organization (WHO)”. We reviewed and documented the information related with the current and future aspects for the management and cure of COVID-19. As of 21st July 2020 a total of 14,562,550 confirmed cases of coronavirus and 607,781 deaths have been reported world-wide. The main clinical feature of COVID-19 ranges from asymptomatic disease to mild lower respiratory tract illness to severe pneumonia, acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and death. The drugs at present used in COVID-19 patients and ongoing clinical trials focusing on drug repurposing of various therapeutic classes of drug e.g. antiviral, anti-inflammatory and/or immunomodulatory drugs along with adjuvant/supportive care. Many drugs on clinical trials shows effective results on preliminary scale and now used currently in patients. Adjuvant/supportive care therapy are used in patients to get the best results in order to minimize the short and long-term complications. However, further studies and clinical trials are needed on large scale of population to reach any firm conclusion in terms of its efficacy and safety. 相似文献
44.
45.
ObjectiveGrowing evidence demonstrates that perceived discrimination and racism are significant contributing factors to psychological distress, low-grade chronic inflammation, and cardiovascular health disparities among minorities, particularly among Black women. Despite this evidence, there are no evidence-based complementary therapy interventions available to ameliorate chronic stress associated with racism and discrimination. The purpose of this study was to examine the feasibility and effectiveness of a novel, 8-week, group-based stress reduction program, Resilience, Stress and Ethnicity (RiSE), designed to help Black women at risk for cardiovascular disease (CVD) develop effective coping skills for dealing with chronic stress uniquely associated with being a minority.MethodsWe conducted two semi-structured focus groups with Black women (N = 22) following their participation in the 8-week RiSE program. We analyzed the data using constant comparative qualitative methods.ResultsAttrition rate was low (13%) with all participants attending at least 6 of the 8 classes. Participants reported high levels of satisfaction with the program and the majority (81%) reported practicing the skills that they learned in real-life stressful situations. In describing the participants’ response to the program, four key categories emerged from the data: (1) Increasing awareness of stressors associated with perceived discrimination and racism; (2) Coping with race-based stressors; (3) Coping with other sources of stress; and (4) Increasing sense of empowerment and emotion regulation.ConclusionsFindings suggest that RiSE is feasible and effective in helping Black women at risk for CVD cope with chronic stress associated with being a minority. Given evidence that perceived discrimination and racism are underlying factors in many inflammatory-based chronic diseases, this research may have broader implications for reducing health disparities across a wide-spectrum of chronic illnesses in which women minorities are disproportionately affected. 相似文献
46.
47.
Due to the optimal results obtained in kidney transplantation and to the lack of interest of the industries, new innovative drugs in kidney transplantation are difficult to be encountered. The best strategy to find the new drugs recently developed or under development is to search in the sections of kidney trans plantation still not completely covered by the drugs on the market. These unmet needs are the prevention of delayed graft function (DGF), the protection of the graft over the long time and the desensitization of preformed anti human leukocyte antigen antibodies and the treatment of the acute antibody-mediated rejection. These needs are particularly relevant due to the expansion of some kind of kidney transplantation as transplantation from non-heart beating donor and in the case of antibody-incompatible grafts. The first are particularly exposed to DGF, the latter need a safe desensitization and a safe treatments of the antibody mediated rejections that often occur. Particular caution is needed in treating these drugs. First, they are described in very recent studies and the follow-up of their effect is of course rather short. Second, some of these drugs are still in an early phase of study, even if in well-conducted randomized controlled trials. Particular caution and a careful check need to be used in trials launched 2 or 3 years ago. Indeed, is always necessary to verify whether the study is still going on or whether and why the study itself was abandoned. 相似文献
48.
49.
50.